Table 3 Summary of dropout pattern by treatment in first- and second-line trials

From: Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

 

First-line trial

Second-line trial

Instrument/ pattern

Panitumumab + FOLFOX4 n (%)

FOLFOX4 alone n (%)

P

Panitumumab + FOLFIRI n (%)

FOLFIRI alone n (%)

P

EQ-5D HSI (n)

279

289

0.010

262

265

0.017

 Early dropout

145 (52.0)

181 (62.6)

 

158 (60.3)

186 (70.2)

 

 Late dropout/completer

134 (48.0)

108 (37.4)

 

104(39.7)

79 (29.8)

 

EQ-5D VAS (n)

278

285

0.050

257

259

0.008

 Early dropout

148 (53.2)

175 (61.4)

 

153 (59.5)

183 (70.7)

 

 Late dropout/completer

130 (46.8)

110 (38.6)

 

104 (40.5)

76 (29.3)

 
  1. Abbreviations: EQ-5D=EuroQoL-5 dimensions; FOLFIRI=fluorouracil, leucovorin and irinotecan; FOLFOX=fluorouracil, leucovorin and oxaliplatin; HSI=Health State Index; VAS=Visual Analogue Scale.
  2. Note: early drop out is defined as study dropout on or before week 28 for the first-line trial and week 20 for the second-line trial. P-value is derived from a χ2-test of association.
Back to article page